Table 3. Associations of TP53 mutations with estimates of immune cell levels across TCGA cohorts.
| Cohort | Sig | Variant | Association |
|---|---|---|---|
| Bladder Cancer | NK | TP53 G245S | 2.63 (4.2) |
| Breast (Basal) | NK | TP53 W91 stop | 2.91 (1.6) |
| Breast Cancer | Bcell | TP53 mutant | 0.29 (3.1) |
| Breast Cancer | NK | TP53 W91 stop | 3.24 (1.9) |
| Breast Cancer | NK | TP53 mutant | 0.26 (3.7) |
| Breast Cancer | TCD8 | TP53 mutant | 0.25 (1.7) |
| Breast Cancer | Tcell | TP53 mutant | 0.26 (2.4) |
| Breast Cancer | Treg | TP53 mutant | 0.51 (18.4) |
| Breast Cancer | TregCD8 | TP53 mutant | 0.26 (3.3) |
| Colon (MSS) | NK | TP53 S94 stop | 3.38 (6.2) |
| Colon (MSS) | NKCD8 | TP53 S94 stop | 3.02 (2) |
| Colon Cancer | NK | TP53 S94 stop | 3.17 (3.5) |
| Head and Neck Cancer | Bcell | TP53 mutant | -0.5 (6.1) |
| Head and Neck Cancer | NK | TP53 mutant | -0.48 (8.3) |
| Head and Neck Cancer | TCD8 | TP53 mutant | -0.66 (13.2) |
| Head and Neck Cancer | Tcell | TP53 mutant | -0.45 (5) |
| Head and Neck Cancer | TregCD8 | TP53 mutant | 0.41 (4.7) |
| Head and Neck Cancer | TregCD8 | TP53 N239D | -2.41 (2.5) |
| Lung Adenocarcinoma | NK | TP53 E224 splice | 4.46 (6.7) |
| Lung Adenocarcinoma | NK | TP53 R249S | 5.31 (7.5) |
| Lung Adenocarcinoma | NKCD8 | TP53 R249S | 4.33 (4.2) |
| Lung Adenocarcinoma | NKCD8 | TP53 E224 splice | 4.85 (6.9) |
| Lung Squamous Cell Carcinoma | NK | TP53 R158H | 3.14 (2.5) |
| Stomach Cancer | NK | TP53 I195N | 2.49 (2.8) |
Values are reported as Effect Size with associated P values in parenthesis (-log10 P). The units of effect size are change in signature score (units of standard deviation) for mutant versus wild type.